These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 10468612)

  • 1. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.
    Gobert C; Skladanowski A; Larsen AK
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10355-60. PubMed ID: 10468612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of DNA topoisomerase I activity by p53.
    Gobert C; Bracco L; Rossi F; Olivier M; Tazi J; Lavelle F; Larsen AK; Riou JF
    Biochemistry; 1996 May; 35(18):5778-86. PubMed ID: 8639538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A camptothecin-resistant DNA topoisomerase I mutant exhibits altered sensitivities to other DNA topoisomerase poisons.
    Knab AM; Fertala J; Bjornsti MA
    J Biol Chem; 1995 Mar; 270(11):6141-8. PubMed ID: 7890748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An engineered mutant of vaccinia virus DNA topoisomerase I is sensitive to the anti-cancer drug camptothecin.
    Gupta M; Zhu CX; Tse-Dinh YC
    J Biol Chem; 1992 Dec; 267(34):24177-80. PubMed ID: 1332948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Covalent and noncovalent DNA binding by mutants of vaccinia DNA topoisomerase I.
    Morham SG; Shuman S
    J Biol Chem; 1992 Aug; 267(22):15984-92. PubMed ID: 1322412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.
    El-Hizawi S; Lagowski JP; Kulesz-Martin M; Albor A
    Cancer Res; 2002 Jun; 62(11):3264-70. PubMed ID: 12036943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I.
    Gromova II; Kjeldsen E; Svejstrup JQ; Alsner J; Christiansen K; Westergaard O
    Nucleic Acids Res; 1993 Feb; 21(3):593-600. PubMed ID: 8382801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin.
    Madden KR; Champoux JJ
    Cancer Res; 1992 Feb; 52(3):525-32. PubMed ID: 1310066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 dependence of topoisomerase I recruitment in vivo.
    Mao Y; Okada S; Chang LS; Muller MT
    Cancer Res; 2000 Aug; 60(16):4538-43. PubMed ID: 10969804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type and mutant forms of p53 activate human topoisomerase I: a possible mechanism for gain of function in mutants.
    Albor A; Kaku S; Kulesz-Martin M
    Cancer Res; 1998 May; 58(10):2091-4. PubMed ID: 9605749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The covalent eukaryotic topoisomerase I-DNA intermediate catalyzes pH-dependent hydrolysis and alcoholysis.
    Christiansen K; Knudsen BR; Westergaard O
    J Biol Chem; 1994 Apr; 269(15):11367-73. PubMed ID: 8157668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of the growth suppressor p53 protein to the cell cycle regulator phosphatase cdc25C.
    Rief N; Herges H; Prowald A; Götz C; Montenarh M
    Int J Oncol; 2000 Jul; 17(1):189-95. PubMed ID: 10853038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eukaryotic topoisomerase I-mediated cleavage requires bipartite DNA interaction. Cleavage of DNA substrates containing strand interruptions implicates a role for topoisomerase I in illegitimate recombination.
    Christiansen K; Svejstrup AB; Andersen AH; Westergaard O
    J Biol Chem; 1993 May; 268(13):9690-701. PubMed ID: 8387503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
    Jacob S; Aguado M; Fallik D; Praz F
    Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p53 protein is an unusually shaped tetramer that binds directly to DNA.
    Friedman PN; Chen X; Bargonetti J; Prives C
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3319-23. PubMed ID: 8475074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
    Chen J; Lin J; Levine AJ
    Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissociation of DNA binding and in vitro transcriptional activities dependent on the C terminus of P53 proteins.
    Kaku S; Albor A; Kulesz-Martin M
    Biochem Biophys Res Commun; 2001 Jan; 280(1):204-11. PubMed ID: 11162500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of polyomavirus DNA replication by wild-type p53 through the DNA-binding site.
    Kanda T; Segawa K; Ohuchi N; Mori S; Ito Y
    Mol Cell Biol; 1994 Apr; 14(4):2651-63. PubMed ID: 8139565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53.
    Zhang W; Shay JW; Deisseroth A
    Cancer Res; 1993 Oct; 53(20):4772-5. PubMed ID: 8402659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 stimulates human topoisomerase I activity by modulating its DNA binding.
    Søe K; Grosse F
    Nucleic Acids Res; 2003 Nov; 31(22):6585-92. PubMed ID: 14602918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.